Lestaurtinib

Drug Profile

Lestaurtinib

Alternative Names: CEP-701; KT 5555; SPM 924

Latest Information Update: 25 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyowa Hakko
  • Developer Cephalon; Children's Oncology Group; Icahn School of Medicine at Mount Sinai; Kyowa Hakko; National Cancer Institute (USA); Teva Pharmaceutical Industries
  • Class Antineoplastics; Carbazoles; Indoles; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase II Acute myeloid leukaemia; Myelofibrosis; Polycythaemia vera; Thrombocytosis
  • Discontinued Multiple myeloma; Pancreatic cancer; Plaque psoriasis; Prostate cancer

Most Recent Events

  • 25 Jan 2018 Lestaurtinib is still in phase III trials for Acute lymphoblastic leukaemia (Combination therapy, In infants, Newly diagnosed) in USA, New Zealand, Canada and Australia (PO) (NCT00557193)
  • 15 Dec 2016 Biomarkers information updated
  • 04 Sep 2015 Phase-II development for Acute myeloid leukaemia (Second-line therapy or greater, Combination therapy), Myelofibrosis, Polycythaemia vera and Thrombocytosis is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top